Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
SAB Biotherapeutics, Inc. (SABS) had Debt to Capital Ratio of 0.13 for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.20M |
|
-- |
|
-- |
|
$10.77M |
|
$-10.77M |
|
$5.58M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-5.20M |
|
$-10.77M |
|
$-10.01M |
|
9.29M |
|
9.29M |
|
$-0.56 |
|
$-0.56 |
|
| Balance Sheet Financials | |
$16.30M |
|
$14.61M |
|
$21.82M |
|
$38.12M |
|
$9.65M |
|
$3.24M |
|
$7.06M |
|
$16.71M |
|
$21.41M |
|
$21.41M |
|
$21.41M |
|
9.29M |
|
| Cash Flow Statement Financials | |
$-7.80M |
|
$4.67M |
|
$-0.17M |
|
$8.90M |
|
$5.64M |
|
$-3.26M |
|
$0.61M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.69 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.13 |
0.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.28% |
|
-24.28% |
|
-13.63% |
|
-21.09% |
|
$2.30 |
|
$-0.84 |
|
$-0.84 |
|